Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Da...Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Data has emerged over recent years regarding the utility of adjuvant chemotherapy for improving disease-free and overall survival of patients following curative resection. This paper reviews the clinical trials that have been conducted in this area along with the studies integrating radiation therapy in the adjuvant setting. The role of prognostic gene signatures are reviewed as well as ongoing clinical trials including those incorporating biological or targeted therapies.展开更多
Lung cancer is responsible for the most cancer deaths worldwide with an incidence that is still rising. One third of patients have unresectable stage ⅢA or stage ⅢB disease. The standard of care for locally advanced...Lung cancer is responsible for the most cancer deaths worldwide with an incidence that is still rising. One third of patients have unresectable stage ⅢA or stage ⅢB disease. The standard of care for locally advanceddisease in patients with good performance status consists of combined modality therapy in particular concurrent chemoradiotherapy. But despite a lot of efforts done in the past, local control and survival of patients with unresectable stage Ⅲ non-small-cell lung cancer(NSCLC) remains poor. Improving outcomes for patients with unresectable stage Ⅲ NSCLC has therefore been an area of ongoing research. Research has focused on improving systemic therapy, improving radiation therapy or adding a maintenance therapy to consolidate the initial therapy. Also implementation of newer targeted therapies and immunotherapy has been investigated as well as the option of prophylactic cranial irradiation. This article reviews the latest literature on improving local control and preventing distant metastases. It seems that we have reached a plateau with conventional chemotherapy. Radiotherapy dose escalation did not improve outcome although increasing radiation dose-intensity with new radiotherapy techniques and the use of newer agents, e.g., immunotherapy might be promising. In the future well-designed clinical trials are necessary to prove those promising results.展开更多
47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases)...47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases) treated only by radiotherapy for observation of the therapeutic effects.展开更多
为了分析单药多西他赛治疗老年晚期非小细胞肺癌(non small cell lungcancer,NSCI.C)每3周方案与每周方案疗效与毒性的关系,对72例老年晚期NSCLC患者,其中40例(治疗组)接受每周方案,30~35mg/m^3,持续静脉滴入3h,d1、d8、d1...为了分析单药多西他赛治疗老年晚期非小细胞肺癌(non small cell lungcancer,NSCI.C)每3周方案与每周方案疗效与毒性的关系,对72例老年晚期NSCLC患者,其中40例(治疗组)接受每周方案,30~35mg/m^3,持续静脉滴入3h,d1、d8、d15休2周,为1个周期;32例(对照组)接受每3周方案,70mg/m^2,持续静脉滴入3h,每3周1次,为1个周期。结果治疗组CR、PR、SD、PD率、总有效率及1年生存率分别为2.5%(1/40)、37.5%(15/40)、32.5%(13/40)、27.5%(11/40)、40.0%(16/40)和47.5%(19/40),对照组分别为3.1%(1/32)、34.4%(11/32)、37.5%(12/32)、25.0%(8/32)、37.5%(12/32)和43.8%(14/32)。两者之间有效率和1年生存率差异无统计学意义,P=0.9920;P=0.6500;治疗组Ⅲ度以上骨髓抑制、消化道反应、口腔黏膜炎分别为3(7.5%)、6(15.0%)和7例(17.5%),而对照组分别为13(40.6%)、15(46.9%)和20例(62.5%)。两组之间差异有统计学意义,P〈0.05。初步研究结果显示,多西他赛单药每周方案治疗老年晚期NSCLC疗效与每3周方案大致相同,但不良反应轻微,更易被耐受。展开更多
文摘Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Data has emerged over recent years regarding the utility of adjuvant chemotherapy for improving disease-free and overall survival of patients following curative resection. This paper reviews the clinical trials that have been conducted in this area along with the studies integrating radiation therapy in the adjuvant setting. The role of prognostic gene signatures are reviewed as well as ongoing clinical trials including those incorporating biological or targeted therapies.
文摘Lung cancer is responsible for the most cancer deaths worldwide with an incidence that is still rising. One third of patients have unresectable stage ⅢA or stage ⅢB disease. The standard of care for locally advanceddisease in patients with good performance status consists of combined modality therapy in particular concurrent chemoradiotherapy. But despite a lot of efforts done in the past, local control and survival of patients with unresectable stage Ⅲ non-small-cell lung cancer(NSCLC) remains poor. Improving outcomes for patients with unresectable stage Ⅲ NSCLC has therefore been an area of ongoing research. Research has focused on improving systemic therapy, improving radiation therapy or adding a maintenance therapy to consolidate the initial therapy. Also implementation of newer targeted therapies and immunotherapy has been investigated as well as the option of prophylactic cranial irradiation. This article reviews the latest literature on improving local control and preventing distant metastases. It seems that we have reached a plateau with conventional chemotherapy. Radiotherapy dose escalation did not improve outcome although increasing radiation dose-intensity with new radiotherapy techniques and the use of newer agents, e.g., immunotherapy might be promising. In the future well-designed clinical trials are necessary to prove those promising results.
文摘47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases) treated only by radiotherapy for observation of the therapeutic effects.
文摘为了分析单药多西他赛治疗老年晚期非小细胞肺癌(non small cell lungcancer,NSCI.C)每3周方案与每周方案疗效与毒性的关系,对72例老年晚期NSCLC患者,其中40例(治疗组)接受每周方案,30~35mg/m^3,持续静脉滴入3h,d1、d8、d15休2周,为1个周期;32例(对照组)接受每3周方案,70mg/m^2,持续静脉滴入3h,每3周1次,为1个周期。结果治疗组CR、PR、SD、PD率、总有效率及1年生存率分别为2.5%(1/40)、37.5%(15/40)、32.5%(13/40)、27.5%(11/40)、40.0%(16/40)和47.5%(19/40),对照组分别为3.1%(1/32)、34.4%(11/32)、37.5%(12/32)、25.0%(8/32)、37.5%(12/32)和43.8%(14/32)。两者之间有效率和1年生存率差异无统计学意义,P=0.9920;P=0.6500;治疗组Ⅲ度以上骨髓抑制、消化道反应、口腔黏膜炎分别为3(7.5%)、6(15.0%)和7例(17.5%),而对照组分别为13(40.6%)、15(46.9%)和20例(62.5%)。两组之间差异有统计学意义,P〈0.05。初步研究结果显示,多西他赛单药每周方案治疗老年晚期NSCLC疗效与每3周方案大致相同,但不良反应轻微,更易被耐受。